Skip to main content

17-09-2018 | Rheumatoid arthritis | Article

Low persistence rates in rheumatoid arthritis patients treated with triple therapy are attributed to adverse drug events associated with sulfasalazine

Erhardt DP et al. Arthritis Care Res (Hoboken) 2018. doi: 10.1002/acr.23759

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics